Itolizumab is under clinical development by Equillium and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Itolizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Itolizumab overview
Itolizumab (T1h, Alzumab / Anti-CD6 ) is a humanized recombinant anti-CD6 monoclonal antibody. It is formulated as injection solution for intravenous infusion. It is indicated for the treatment of patients with active moderate to severe chronic plaque psoriasis who are candidates for systemic therapy. Alzumab is indicated for emergency use in the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19.
Itolizumab is under development for the treatment of systemic lupus erythematosus, acute graft-versus-host disease (aGVHD), lupus nephritis, ulcerative colitis and chronic graft-versus-host disease (cGVHD). It is administered through intravenous and subcutaneous route.
It was also under development for the treatment of Coronavirus disease 2019 (COVID-19), vitiligo, psoriatic arthritis, psoriasis, rheumatoid arthritis, multiple sclerosis, dermatological disorders, refractory lupus nephritis and severe asthma.
Equillium overview
Equillium is a biotechnology business that specialises in immunobiology to develop drugs for the treatment of autoimmune and inflammatory illnesses.The company’s pipeline product includes EQ001 (itolizumab), a first-in-class monoclonal antibody that targets the novel immune checkpoint receptor CD6 that inhibits pathogenic cellular pathways for effector T cell development. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium develops its products for immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, gastrointestinal, renal and vascular. Equillium is headquartered in La Jolla, California, the US.
For a complete picture of Itolizumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
